Laura was also a Role Model for the Women of the Future Conference 2015, when she was working with MedImmune:
Laura is a cell biologist working as part of a global team with over 80 scientist across Cambridge, UK and Maryland,USA. The team is subdivided into different disease therapy areas with the objective of understanding the cellular and molecular interactions involved in modulating diseases such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD) , non-alcoholic steatohepatitis (NASH), Rheumatoid arthritis (RA) , inflammatory bowel disease (IBD) and systemic lupus erythematosus (SLE).
Laura is currently the biology lead for NASH, which is one of MedImmunes newest disease areas and amongst the most common liver diseases in the West. Laura is primarily responsible for developing cellular assays that depict the inflammation and fibrosis observed in NASH, in addition to driving and establishing new collaborations within Medimmune. She has over 10 years experience in the biotech industry developing cellular assays for protein therapeutic drugs spanning multiple disease areas. She was part of the team that identified the anti GM-CSF receptor, Marilimumab, which is currently in Phase 2b clinical trials for Rheumatoid arthritis.
Laura has an MSc in Immunology and BSc in Physiology/Pharmacology from the University of the West of England, Bristol.